Evidence map›Paper›PMID 40009680›Full record

ReviewScience advances2025

Leveraging nature's nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications.

Yunxi Chen, Noélie Douanne, Tad Wu, Ishman Kaur, Thupten Tsering, Armen Erzingatzian, Amélie Nadeau, David Juncker, Vahé Nerguizian, Julia V Burnier

Abstract readReview
In one paragraph

Review in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yunxi ChenCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID 0000-0001-7575-2686
Noélie DouanneCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Tad WuCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Ishman KaurCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Thupten TseringCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID 0000-0002-4613-5790
Armen ErzingatzianCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Amélie NadeauCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID 0009-0009-7074-0112
David JunckerDepartment of Biomedical Engineering and Victor Philippe Dahdaleh Institute of Genomic Medicine, McGill University, Montreal, QC, Canada.ORCID 0000-0002-7313-1162
Vahé NerguizianÉcole de technologie supérieure ÉTS, Montreal, QC, Canada.ORCID 0000-0002-0885-5113
Julia V BurnierCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID 0000-0002-2184-2157

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Naturally occurring extracellular vesicles (EVs) and synthetic nanoparticles like liposomes have revolutionized precision diagnostics and medicine. EVs excel in biocompatibility and cell targeting, while liposomes offer enhanced drug loading capacity and scalability. The clinical translation of EVs is hindered by challenges including low yield and heterogeneity, whereas liposomes face rapid immune clearance and limited targeting efficiency. To bridge these gaps, biomimetic synthetic vesicles (SVs) have emerged as innovative platforms, combining the advantageous properties of EVs and liposomes. This review emphasizes critical aspects of EV biology, such as mechanisms of EV-cell interaction and source-dependent functionalities in targeting, immune modulation, and tissue regeneration, informing biomimetic SV engineering. We reviewed a broad array of biomimetic SVs, with a focus on lipid bilayered vesicles functionalized with proteins. These include cell-derived nanovesicles, protein-functionalized liposomes, and hybrid vesicles. By addressing current challenges and highlighting opportunities, this review aims to advance biomimetic SVs for transformative biomedical applications.

Indexed as

Biomimetic MaterialsBiomimeticsDrug CarriersExtracellular VesiclesNanoparticlesAnimalsDrug Delivery SystemsHumansLiposomesDrug CarriersLiposomes

Identifiers

PMID40009680
PMCPMC11864201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.